COMBINATION IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA

• DOI: 10.48286/aro.2021.10
• Publication Date: 2021-12-15T13:57:45Z
• Authors: P. Sepe; A. Ottini; E. Verzoni; V. Guadalupi; M. Claps; G. Procopio
• Keywords: 03 medical and health sciences; 0302 clinical medicine

Various treatments have been considered as the cornerstone for management of patients with metastatic renal cell carcinoma (mRCC) over past two decades.Currently, immunotherapy is a promising clue in landscape frontline treatment mRCC.Immune checkpoint inhibitors (ICIs), which constitute standard therapy pretreated mRCC patients, are emerging possible earlier treatment's strategy mRCC.Otherwise, antiangiogenetics well established backbone mRCC, and research now focused on development innovative tyrosine kinase (TKIs).Frontline combination